NYSE:AVNSAvanos Medical Stock Price, Forecast & News

Avanos Medical's stock was trading at $29.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AVNS shares have increased by 0.4% and is now trading at $29.12. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Avanos Medical.

Avanos Medical is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Avanos Medical.

Avanos Medical Inc (NYSE:AVNS) issued its quarterly earnings results on Wednesday, May, 6th. The company reported $0.16 EPS for the quarter, hitting analysts' consensus estimates of $0.16. The firm had revenue of $180.40 million for the quarter, compared to the consensus estimate of $175.15 million. Avanos Medical had a negative net margin of 3.07% and a positive return on equity of 4.09%. The company's revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.15 EPS. View Avanos Medical's earnings history.

7 analysts have issued twelve-month price objectives for Avanos Medical's stock. Their forecasts range from $30.00 to $48.00. On average, they expect Avanos Medical's stock price to reach $36.00 in the next year. This suggests a possible upside of 23.6% from the stock's current price. View analysts' price targets for Avanos Medical.

Media headlines about AVNS stock have trended extremely negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Avanos Medical earned a coverage optimism score of -4.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutAvanos Medical.

Avanos Medical saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 2,810,000 shares, an increase of 12.0% from the March 31st total of 2,510,000 shares. Based on an average daily volume of 421,500 shares, the days-to-cover ratio is presently 6.7 days. Currently, 6.0% of the shares of the stock are short sold. View Avanos Medical's Current Options Chain.

Some companies that are related to Avanos Medical include MSA Safety (MSA), Wright Medical Group (WMGI), Wound Management Technologies (WNDM), Inogen (INGN), Establishment Labs (ESTA), Invacare (IVC), Sientra (SIEN), RTI Surgical (RTIX), Lakeland Industries (LAKE), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Allied Healthcare Products (AHPI), Histogenics (HSGX), Ocugen (OCGN) and Bionik Laboratories (BNKL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly Clark (KMB), AT&T (T), Alibaba Group (BABA), CVS Health (CVS), Honeywell International (HON), Procter & Gamble (PG), Verizon Communications (VZ), Home Depot (HD), Johnson & Johnson (JNJ) and Altria Group (MO).

Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS."

Avanos Medical's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.35%), Champlain Investment Partners LLC (7.19%), Paradice Investment Management LLC (5.40%), Wellington Management Group LLP (4.71%), State Street Corp (3.73%) and Victory Capital Management Inc. (3.48%). Company insiders that own Avanos Medical stock include Gary Blackford, John W Wesley, Joseph Fralin Woody and Steven E Voskuil. View institutional ownership trends for Avanos Medical.

AVNS stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., BlackRock Inc., Morgan Stanley, Principal Financial Group Inc., Engineers Gate Manager LP, State Street Corp, Arizona State Retirement System, and Palmer Knight Co. View insider buying and selling activity for Avanos Medical.

AVNS stock was bought by a variety of institutional investors in the last quarter, including Paradice Investment Management LLC, Confluence Investment Management LLC, Wells Fargo & Company MN, Champlain Investment Partners LLC, Advisor Group Holdings Inc., Wellington Management Group LLP, Deutsche Bank AG, and Geode Capital Management LLC. Company insiders that have bought Avanos Medical stock in the last two years include Gary Blackford, John W Wesley, Joseph Fralin Woody, and Steven E Voskuil. View insider buying and selling activity for Avanos Medical.

Shares of AVNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AVNS stock can currently be purchased for approximately $29.12.

Avanos Medical has a market capitalization of $1.39 billion and generates $697.60 million in revenue each year. The company earns $-45,900,000.00 in net income (profit) each year or $1.07 on an earnings per share basis. Avanos Medical employs 4,700 workers across the globe.

The official website for Avanos Medical is avanos.com.

Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The company can be reached via phone at 844-428-2667 or via email at [email protected]